Although GLP-1 RAs by themselves have a low risk of hypoglycemia, when used in combination with sulfonylureas and/or insulin, some experts recommend lowering the dose of sulfonylureas and short-acting and low-acting pancreatic islet analogs before or during the use of GLP-1 RAs (Romera et al., 2019; Smits and Van Raalte, 2021). The gene discussed is INS; the disease is Hypoglycemia.